Tue.Nov 05, 2024

article thumbnail

Intra-Cellular's unstoppable Caplyta nails another trial, this time for relapse prevention in schizophrenia

Fierce Pharma

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial.

Medical 317
article thumbnail

CEO with type 1 diabetes works to deliver ‘world’s first’ functional cure

PharmaVoice

Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.

Patients 124
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AstraZeneca stock tanks over fears of expanding China fraud probe

Fierce Pharma

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a local report fueled fears of a potentially escalating insurance fraud investigation in China. | AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially escalating insurance fraud investigation in China.

Insurance 312
article thumbnail

WTW: There’s A Disconnect Between Employers and Employees on Wellbeing Programs

MedCity News

Employers are prioritizing mental wellbeing programs, but employees say they need financial wellbeing support, according to a survey from WTW. The post WTW: There’s A Disconnect Between Employers and Employees on Wellbeing Programs appeared first on MedCity News.

124
124
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Analysts point to Syfovre 'nadir' after Apellis discloses disappointing quarter

Fierce Pharma

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for geographic atrophy (GA), Syfovre, may have hit a performance “nadir” in 2024 | Over the latest earnings stretch, Apellis' Syfovre saw sales down about 2% from the previous quarter despite an overall demand increase of about 7%.

Sales 290
article thumbnail

Reducing Clinical and Staff Burnout with AI Automation

MedCity News

As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers. The post Reducing Clinical and Staff Burnout with AI Automation appeared first on MedCity News.

More Trending

article thumbnail

Why Digital Twin Technology Could Help Maximize GLP-1 Efficacy

MedCity News

Digital twin technology can serve as an effective complement to some of the exciting advancements occurring in the metabolic health space, such as new generations of continuous glucose monitors and a slew of GLP-1s, according to Lisa Shah, chief medical officer at Twin Health. The post Why Digital Twin Technology Could Help Maximize GLP-1 Efficacy appeared first on MedCity News.

Medical 118
article thumbnail

Accord wins £50M joint investment from UK to bolster local production of cancer, immunology drugs

Fierce Pharma

As the U.K. works to pump fresh cash into the local biopharma scene, London’s Accord Healthcare is capitalizing on the government’s renewed willingness to chip in. | Flush with a 50 million pound sterling ($65 million) joint investment deal from the U.K., Accord—one of Europe's top makers of generic chemotherapies—is embarking on an expansion of its Fawdon drug manufacturing facility in Newcastle upon Tyne, England.

Biopharma 245
article thumbnail

Beam points to positive data with key base editing asset

pharmaphorum

Beam shines a light on phase 1/2 data with its base editing candidate for sickle cell disease ahead of a full presentation at ASH next month

115
115
article thumbnail

Vertex's Casgevy breaks ground with 1st commercial patient infusions as company readies another major launch for 2025

Fierce Pharma

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta thalassemia, “there has never been a more exciting time to be at Vertex,” c | With its first Casgevy revenues in the books, Vertex lifted its full-year sales outlook as it turns its attention to two product launches in 2025, including an expected new entrant in the pain market.

Patients 312
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Disc maps out US filing for porphyria drug bitopertin

pharmaphorum

Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.Shares in the company gained almost 24% after it announced that the end of phase 2 meeting with the US regulator had firmed up plans for a phase 3 trial of bitopertin in EPP, as well as the potential for accelerated approval.

Medicine 110
article thumbnail

Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results

MedCity News

The death wasn’t due to Beam Therapeutics’ sickle cell disease therapy, BEAM-101, but was instead attributed to the preconditioning treatment needed before the genetic medicine is infused. A different Beam program in preclinical development could avoid the need for toxic preconditioning; data from both programs will be presented during the upcoming American Society of Hematology annual meeting.

Medicine 110
article thumbnail

Journey slips on FDA approval of rosacea therapy

pharmaphorum

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.The new capsule formulation of the antibiotic minocycline hydrochloride has been cleared by the US regulator to treat the inflammatory lesions caused by rosacea – which causes flushing or long-term redness and pustules on the face – in adults.

FDA 116
article thumbnail

WTW: There’s A Disconnect Between Employers and Employees on Wellbeing Programs

MedCity News

Employers are prioritizing mental wellbeing programs, but employees say they need financial wellbeing support, according to a survey from WTW. The post WTW: There’s A Disconnect Between Employers and Employees on Wellbeing Programs appeared first on MedCity News.

105
105
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

CRUK backs AI-powered, virtual radiotherapy trial projects

pharmaphorum

Cancer Research UK awards £5.

110
110
article thumbnail

Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA

Pharmaceutical Technology

Ascendis Pharma will license its TransCon technology to Novo to develop therapies for metabolic and cardiovascular diseases.

Pharma 97
article thumbnail

AZ shares weaken as China investigation rumours swirl

pharmaphorum

AstraZeneca's shares have fallen more than 8% on speculation about an anti-corruption probe in China, its second-largest market, wiping around $14 billion off its value.The sell-off appears to have been prompted by an article in Chinese financial media outlet Yicai which suggested that "dozens of senior executives" at AZ's Chinese subsidiary have been implicated in an ongoing insurance fraud case.

Insurance 115
article thumbnail

Study Finds Behaviors of Breast Cancer Cells Help Predict Risk of Bone Metastasis

Pharmacy Times

Using in vitro models, study investigators predict the risk of bone metastasis in breast cancer based on correlations with their in vivo behaviors and potential.

61
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Oxford Nanopore and UK to develop pathogen surveillance system

Pharmaceutical Technology

This initiative brings together UK Biobank, Genomics England, NHS England, and Oxford Nanopore to accelerate genomics-based research in the UK.

59
article thumbnail

Study: Supply Chain Issues Less Likely to Result in Drug Shortages in Canada Compared to United States

Pharmaceutical Commerce

JAMA study indicates Canada may have a more resilient drug supply chain or different thresholds for reporting and responding to issues compared with the United States.

59
article thumbnail

FDA Approves DFD-29 for Treatment of Adults With Rosacea-Related Inflammatory Lesions

Pharmacy Times

The approval comes after the phase 3 clinical trials MVOR-1 (NCT05296629) and MVOR-2 (NCT05343455).

FDA 57
article thumbnail

From neurosurgery to focused ultrasound: Not if, but when

pharmaphorum

Therapeutic or focused ultrasound began being applied to neurologic conditions less than a decade ago, but its potential in a wide spectrum of brain applications is high. In today’s podcast, web editor Nicole Raleigh speaks with Dr Neal Kassell, chair and founder of the Focused Ultrasound Foundation and previously a neurosurgeon, who created the Foundation in 2006 to improve the lives of millions of people with serious medical disorders by accelerating the development and adoption of focused ult

Medical 105
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Dupilumab Shows Significant Reductions in Itch and Hive Activity in Patients With CSU

Pharmacy Times

About 41% and 30% of patients with chronic spontaneous urticaria (CSU), respectively, achieved well-controlled disease status and complete response when treated with dupilumab.

article thumbnail

Encouraging data revealed for schizophrenia long-acting injectables

European Pharmaceutical Review

New data presented at Psych Congress 2024 has shown that the olanzapine long-acting injectable (LAI) TEV-‘749 / mdc-TJK demonstrated “significant improvement” in social functioning and quality of life in adults with schizophrenia. This was based on findings from the initial period (up to week 8) of the Phase III SOLARIS trial. According to Medincell, TEV-‘749 could be the first long-acting olanzapine medication with a favourable safety profile, because “other LAIs of olanzapine have been associa

article thumbnail

Pharmacists Play Key Role in Flu Vaccination Efforts

Pharmacy Times

Kristi Veis discusses the importance of flu vaccinations and the role of pharmacists in administering them.

52
article thumbnail

Revolutionizing Patient Care: The Top Five Benefits of Investing in Innovation

Pharmaceutical Commerce

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Researchers Find Lack of Communication for Lung Cancer Screenings Among High-Risk Individuals

Pharmacy Times

Less than 16% of high-risk lung cancer individuals have heard or discussed lung cancer screenings with a health care provider.

52
article thumbnail

Untethered Data: Unifying and Contextualizing Drug Discovery Data

PharmaTech

Capturing and curating R&D data are crucial to realizing the full value of advanced analytics.

52
article thumbnail

The Essentials of Banking Sales in Malaysia: Navigating Customer Expectations and Market Dynamics

Contrarian Sales Techniques

Understanding the Malaysian Banking Scene In Malaysia, banking isn’t just about selling products—it’s about building trust and understanding each customer’s unique needs. As a sales professional in this market, connecting with clients goes beyond financial discussions; it’s about forming genuine relationships. Whether it’s helping someone with a personal loan, guiding a small business owner, or introducing a client to Islamic banking products, a thoughtful approach is key.

Sales 52
article thumbnail

High-Sensitivity Quantitation of Nitrosamine Impurities and NDSRI in Drug Substances and Products Using LC-MS/MS

PharmaTech

Webinar Date/Time: Wed, Dec 11, 2024 11:00 AM EST

52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A